Digestive Disease Week (DDW) 2026

Chicago, Illinois, US 02 May 2026 - 05 May 2026

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026 by

Icotrokinra—the first and only targeted oral peptide designed to selectively block the interleukin-23 receptor (IL-23R), which has been approved for the treatment of plaque psoriasis—shows multiple favourable signals for the treatment of ulcerative colitis (UC), according to updated data from the phase IIb ANTHEM-UC study.

ANTHEM-UC unlocks psoriasis drug potential in ulcerative colitis

26 May 2026

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026 by

Treatment with guselkumab resulted in significantly higher rates of combined fistula remission at week 24 in adults with active perianal fistulizing Crohn’s disease (PFCD) compared with placebo, according to the FUZION trial presented at DDW 2026.

Guselkumab shows efficacy in perianal fistulizing Crohn’s disease

22 May 2026

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026 by

Results from the phase III TRIUMpH-EE study demonstrate the superiority of the novel potassium-competitive acid blocker (P-CAB) tegoprazan over the proton pump inhibitor (PPI) lansoprazole in providing faster healing of erosive esophagitis (EE) and heartburn relief.

Tegoprazan TRIUMpHs as PPI alternative for erosive esophagitis, heartburn

21 May 2026

Novel robotic colonoscopy system performs well in first-in-human study

18 May 2026 by

A robotic colonoscopy system has been shown to be safe and feasible in the first-in-human CARE study, with successful completion of the procedure achieved in all cases and no major adverse events.

Novel robotic colonoscopy system performs well in first-in-human study

18 May 2026

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026 by

A top-down approach of initiating treatment with infliximab plus immunomodulator upon diagnosis of Crohn’s disease (CD) reduces the risk of related abdominal surgery, as well as those of disease progression and hospitalization, as compared with the conventional step-up approach, according to long-term data from the PROFILE trial.

5-year PROFILE data: Top-down therapy able to modify longer-term course of CD

17 May 2026

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

16 May 2026 by

Exposure to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrates superiority over current FDA-approved pharmacotherapies for alcohol use disorder (AUD), reducing the risk of AUD after 1 year of therapy, reports a study presented at DDW 2026.

GLP-1 RA prevents relapse, cuts weight in AUD patients with MetD

16 May 2026

Whole-food diet helps ease Crohn’s disease severity

15 May 2026 by

Patients with mild-to-moderate Crohn’s disease (CD) who received the Crohn’s Disease Therapeutic Dietary Intervention (CD-TDI) demonstrate clinical, inflammatory, and barrier improvements, as well as more than threefold greater response than those who received conventional management, reports a study presented at DDW 2026.

Whole-food diet helps ease Crohn’s disease severity

15 May 2026

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

15 May 2026 by

Treatment with either dose of linaclotide (72 or 145 µg) showed improves bowel movement frequency and abdominal symptoms in adults with severe chronic idiopathic constipation (CIC), according to a post hoc pooled analysis of phase III studies presented at DDW 2026.

Linaclotide improves bowel movements, abdominal symptoms in adults with severe CIC

15 May 2026